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Abstract: Triggering receptor expressed on my-
eloid cells-1 (TREM-1) is amember of a new family of
myeloid receptors, encoded by a gene cluster linked
to the MHC. Engagement of TREM-1 stimulates in-
tracellular signals, resulting in activation of phagocy-
tosis, neutrophil degranulation, and amplification of
cytokine production induced by TLRs. In the present
study, a novel property following engagement of
TREM-1 is described, namely the amplification of
cytokine production induced by the second major
class of pattern recognition receptors, the NAIP, CI-
ITA, HET-E, TP-1-leucine-rich repeat (NACHT-
LRR; NLR) receptors, which recognize intracellular
microorganisms through sensing their muropeptide
components of peptidoglycan. The TREM-1/NLR
synergism was observed for the production of
TNF-, IL-1, and IL-6, leading to an increase in
cytokine production up to tenfold greater than the
additive value of TREM-1 or muropeptide stimula-
tion alone. Several putative mechanisms are proposed
to be involved in the synergism between NLRs and
TREM-1, including the increase in TREM-1 expres-
sion by NLR ligands, and of the expression of nucle-
otide oligomerization domain-2 receptor by TREM-1
engagement. In contrast, although caspase-1 modu-
lates IL-1 and IL-6 production after stimulation
with anti-TREM-1 antibodies or NLR ligands, it does
not appear to be responsible for the synergism be-
tween these two pathways. These findings demon-
strate that TREM-1 acts on both major recognition
pathways of bacterial structures: the extracellular
TLR receptors, and the intracellular NLRmolecules.
This latter finding supports the concept that TREM-1
provides optimal amplification of cytokine-induced
inflammation during the initiation of host defense. J.
Leukoc. Biol. 80: 1454–1461; 2006.
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INTRODUCTION
During the initial phase of the host defense, the innate immune
system relies mainly on the coordinated action of phagocytes
and NK cells. These cells recognize microorganisms through
pattern recognition receptors (PRRs), resulting in the release of
proinflammatory cytokines and phagocyte activation [1]. Mi-
crobial recognition is accomplished by two main classes of
PRRs: the TLRs, which are expressed primarily on the surface
of the cell membrane, are responsible for recognition of extra-
cellular microbial components [2], whereas the cytoplasmic
NAIP, CIITA, HET-E, TP-1-leucine-rich repeat (NACHT-
LRR; NLR) receptors are the main recognition system of
intracellular microorganisms and their ligands [3]. However,
efficient activation of host defense mechanisms by these re-
ceptors requires amplification signals provided by additional
routes such as lectin-like molecules (e.g., dectin-1, mannose
receptors) [4, 5], high-mobility group box protein-1 [6], and a
newly described class of molecules on the surface of leuko-
cytes, called triggering receptors expressed on myeloid cells
(TREMs) [7].
TREM-1 is a 30-kDa glycoprotein of the Ig family, consist-
ing of a single extracellular Ig-like domain of the V-type, a
transmembrane region, and a short intracytoplasmic tail [8].
TREM-1 is expressed on neutrophil and monocytes, whereas
TREM-2 is a family member which is expressed on macro-
phages and dendritic cells [7]. Both receptors associate with
DNAX-activating protein 12 (DAP12) for signaling, and
TREM-1 engagement triggers TNF, IL-8, and MCP-1 produc-
tion, as well as neutrophil degranulation and release of NO [9,
10]. It has been also proposed that TREM-1 provides a vital
amplification loop for the proinflammatory responses induced
by TLR ligands [10, 11]. This concept has been validated in
animal models characterized by overwhelming inflammation
(e.g., lethal endotoxaemia, Escherichia coli peritonitis, caecal
ligation, and puncture), in which neutralization of TREM-1
prevented hyperinflammatory responses and death [12].
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We hypothesized that engagement of TREM-1 amplifies not
only the TLR-dependent signals but also the activation of
NLR-dependent pathways. Engagement of NLRs by the mu-
ropeptide components of bacterial peptidoglycans activates the
NF-B pathway and proinflammatory cytokine production [3,
13]. In this respect, the NLR family members nucleotide
oligomerization domain-2 (NOD2) and NALP3 recognize the
muramyl dipeptide (MDP) of Gram-positive bacteria [14–16],
and NOD1 recognizes the meso-diaminopimelic acid-contain-
ing muropeptides (Mur-Tri-DAP) of Gram-negative bacteria
[17]. In the present study, we demonstrate that TREM-1 acti-
vation amplifies the induction of the proinflammatory cytokine
production by bacterial muropeptides, through mechanisms
involving increased NOD2 gene transcription and activation of
caspase-1-dependent pathways.
MATERIALS AND METHODS
Isolation of PBMC and stimulation of cytokine
production by TREM-1 engagement
After informed consent, venous blood was drawn from the antecubital vein of
healthy volunteers into heparin tubes. The PBMC fraction was obtained by
density centrifugation of blood diluted 1:1 in pyrogen-free saline over His-
topaque (Sigma Chemical Co., St. Louis, MO). Cells were washed twice in
saline and suspended in culture medium (RPMI 1640) supplemented with
penicillin (100 U/ml) and streptomycin (100 g/ml).
To activate PBMC through TREM-1, 96-well flat-bottom plates were pre-
coated with 10 g/ml (unless otherwise indicated) of an agonist anti-TREM-1
mAb (Clone 193015, R&D Systems, Minneapolis, MN) or an isotype-matched
control antibody (mouse IgG1, R&D Systems), as previously used also by
others [10]. To study the effects of human plasma, 5% human pooled plasma
was added into some of the wells. After 4 h incubation at 37°C, the wells were
washed with sterile PBS, and 5  105 PBMC in a 200-l vol were added.
Proinflammatory cytokine production was measured in the supernatants after
an additional 24-h incubation. The role of the endogenous TNF, IL-1, or IL-18
in the induction of cytokines by TREM-1 was investigated by preincubating the
PBMC for 30 min with the respective natural cytokine antagonists: TNF-
binding proteins (TNFbp; 10 g/ml, R&D Systems), IL-1 receptor antagonist
(IL-1Ra; 10 g/ml, R&D Systems), or IL-18 binding protein (IL-18BP; 10
g/ml; ref. [18]).
Assessment of the synergistsic activity between
TREM-1 and TLR/NLR ligands
To investigate the effect of TREM-1 engagement on the TLR- and NLR-
induced stimulation, PBMC were added in the wells preincubated with anti-
TREM-1 or control antibodies. In addition, 100 l culture medium (RPMI
1640) or the various TLR ligands were added to the culture: TLR2 was
stimulated with synthetic lipoteichoic acid (LTA; kindly provided by Dr.
Thomas Hartung, University of Konstanz, Germany, 5 g/ml), TLR3 with
polyinosinic:polycytidylic acid (poly I:C; 50 g/ml), TLR4 stimulation with
purified E. coli LPS (1 ng/ml), TLR5 with flagellin (10 ng/ml), and TLR9 with
CpG (5 g/ml). The synergism between IL-32 and the NLR ligands MDP
(0.1–10 g/ml) and MurNAc-L-Ala-D-Glu-meso-diaminopimelic acid (Mur-
Tri-DAP; 1 g/ml) was also investigated. All TLR and NLR ligands were
checked for the contamination with LPS in the Limulus amoebocyte lysate
assay and found to be negative. After 24 h incubation at 37°C, the supernatants
were collected and stored at –70°C until cytokine assays were performed.
Cytokine concentrations were determined by specific electrochemilumines-
cence assays, as described previously [19]. In separate experiments, PBMC
were sequentially incubated for 4 h with anti-TREM-1 antibodies, before
adding the NLR ligands to the cells. Alternatively, the sequence was changed,
and the cells were preincubated with NLR ligands before stimulation with
anti-TREM-1 antibodies.
Stimulation of TREM-1 expression by TLR and
NLR ligands
To investigate the effects of the various TLR and NLR ligands on TREM-1
expression, 5  105 PBMC in a 200-l vol were added to flat-bottom 96-wells
plates and were stimulated for 24 h with the TLR and NLR ligands described
above. After stimulation, 20 l Triton-X 100 was added to the wells to induce
cell-membrane disruption, and the samples were frozen-thawed twice.
TREM-1 concentrations were measured with a commercial sandwich ELISA
from R&D Systems, with a detection limit of 30 pg/ml.
RT-PCR for the NOD2 expression
Ten million freshly isolated PBMC were stimulated with 10 g/ml control
mouse IgG1 or the monoclonal anti-human TREM-1. After 4 h incubation at
37°C, total RNA was extracted in 1 ml TRIzol reagent, an improved single-step
RNA isolation method based on the method described by Chomczynski and
Sacchi [20]. Thereafter, RNA was precipitated with isopropanol, washed with
70% ethanol, and redissolved in water. Isolated RNA was treated with DNase
before being reverse-transcribed into cDNA using oligo(dT) primers and Molo-
ney murine leukemia virus RT. PCR was performed using a Peltier (Water-
town, MA) Thermal Cycler-200. Primer sequences for the NOD2 were: 5-TGG-
TTC-AGC-CTC-TCA-CGA-TG-3 (forward) and 5-TGC-TGA-AGA-GCT-CCT-
CCA-GG-3 (reverse). GAPDH was used as a reference gene, for which the
primers were: 5-GGC-AAA-TTC-AAC-GGC-ACA-3 (forward) and 5-GTT-
AGT-GGG-GTC-TCG-CTC-TG-3 (reverse). PCR conditions were as follows: 2
min at 50°C and 10 min at 95°C, followed by 30 cycles of PCR reaction at
94°C for 45 s, 70°C for 2 min, and 59°C for 1 min. The PCR products were run
on 1% agarose gels stained with ethidium bromide.
The role of caspases for the synergism between
TREM-1 and NLR ligands
To investigate the role of caspases for the synergism between TREM-1 and the
muropeptides MDP and Mur-Tri-DAP, we added 20 M Z-Val-Ala-Asp-fluoro-
methylketone, a pan-caspase inhibitor (Bachem, King of Prussia, PA) to the
medium. In addition, specific inhibition of caspase-1 with 20 M Ac-Tyr-Val-
Ala-Asp-2,6-dimethylbezoyloxymethylketone (Alexis Biochemicals, San Di-
ego, CA) or simultaneous inhibition of caspase-1 and caspase-5 with 20 M
Ac-Trp-Glu-His-Asp-aldehyde (Bachem) was performed. The role of the en-
dogenous IL-1 and IL-18 for the synergistic effects of TREM-1 and muropep-
tides on IL-6 production was investigated by blocking their activity with
IL-1Ra (10 g/ml) or IL-18BP (10 g/ml).
Statistical analysis
The human experiments were performed in triplicate with PBMC obtained from
eight volunteers. The mouse experiments were performed in 10 mice per group
on two different occasions, and the data are presented as cumulative results.
The differences between groups were analyzed by unpaired t-test, and where
appropriate by paired t-test. The data are given as means  SEM.
RESULTS
TREM-1 engagement stimulates cytokine
production in a plasma-dependent manner
When anti-TREM-1 antibodies were added in the liquid phase
to the PBMC, no stimulation of cytokines was apparent. In
contrast, as shown in Figure 1, when the anti-TREM-1 anti-
bodies were fixed on the bottom of the wells, the TREM-1
engagement strongly induced the production of the proinflam-
matory cytokines TNF-, IL-6, and IL-1, probably as a result
of the cross-linking of TREM-1 on the cell membrane. No
stimulation was observed in the presence of the control anti-
body. Addition of human plasma greatly potentiated the cyto-
kine production induced by the anti-TREM-1 antibody (Fig. 1).
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In separate experiments, to investigate whether this stimu-
lation was dependent on the intermediary production of TNF,
IL-1, or IL-18, the cells were preincubated for 30 min with the
natural inhibitors of these cytokines: TNFbp, IL-1Ra, or IL-
18BP. No effects of these inhibitors on the TREM-1-induced
cytokines were apparent, in the absence or in presence of
human plasma, demonstrating that the stimulatory effects of
TREM-1 were direct and not a result of intermediate TNF,
IL-1, or IL-18 (Fig. 2). Positive control stimulation of IL-6 by
TNF and IL-1 or IFN- by IL-18/IL-12 costimulation has
been performed to assess the efficacy of the various cytokine
inhibitors. TNFbp, IL-1Ra, and IL-18BP completely blocked
the biological effects of the respective cytokines (not shown).
TREM-1 amplifies cytokine induction by TLR and
NLR ligands
Optimal induction of proinflammatory cytokines after recogni-
tion of bacteria by the major PRRs needs amplification through
additional pathways. The protective effects of anti-TREM-1
antibodes in models of endotoxic shock suggest that TREM-1
is one of these amplification mechanisms. To test the validity of
this hypothesis, human PBMC were costimulated with anti-
TREM-1 agonistic antibodies and TLR or NLR ligands. As
shown in Figure 3, A and B, TREM-1 synergized with the
signals induced by ligands of TLRs and the muropeptide
ligands of NLRs: MDP (ligand of NOD2, NALP1, and NALP3)
and Mur-Tri-DAP (NOD1). There was a dose-dependent effect
of the anti-TREM-1 concentrations used for coating the plates
(expressed in g/ml) on the synergism with MDP-induced
TNF- (Fig. 3C) and IL-6 (Fig. 3D).
When stimulation of cells was performed sequentially (4 h
prestimulation by anti-TREM-1, followed by NOD2 stimula-
tion), a similar amplification of NOD2 signals was observed: a
Fig. 2. TREM-1 stimulates cytokine synthesis independently of endogenous
TNF, IL-1, or IL-18. Human PBMC were incubated in wells coated with a
monoclonal anti-TREM-1 (aTREM-1) antibody, in the absence or presence of
specific anticytokine inhibitors: IL-18BP, TNFbp, and IL-1Ra (each at 10
g/ml). TNF (open bars) and IL-6 (hatched bars) were measured after stimu-
lation in the absence (A) or in presence (B) of 5% human plasma. Data are
presented as means  SEM (n8).
Fig. 1. TREM-1 engagement stimulates cytokine production. PBMC were
added to antihuman TREM-1 (aTREM-1)-coated wells in the absence (open
bars) or presence (hatched bars) of 5% frozen, pooled human plasma. After 24
incubation, the concentrations of TNF- (A), IL-6 (B), and IL-1 (C) were
measured by specific ECL. Data are presented as means  SEM (n8); *, P 	
0.01.
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threefold higher TNF production compared with NOD2 stimu-
lation alone (P	0.05) and a fivefold enhancement of the pro-
duction of IL-1 (P	0.02). In contrast, no synergism was
observed when cells were first preincubated 4 h with MDP
followed by TREM-1 ligation (TNF production 356127 pg/ml
after MDP stimulation and 524  201 pg/ml after MDP,
followed by anti-TREM-1 antibodies; Pnot significant).
TREM-1 signals induce the expression of NOD2
Several possible mechanisms to explain the synergism between
TREM-1 and NOD2 were investigated. First, the effects of
NLR and TLR ligands on the expression of TREM-1 were
investigated. Human PBMC were stimulated with a panel of
TLR and NLR stimuli. After 24 h, the levels of TREM-1
protein in the cell lysates were measured by a specific ELISA.
Whereas LPS increased twofold the amount of TREM-1, the
other TLR and NLR ligands displayed only a marginal influ-
ence on TREM-1 expression, with 50–70% increase after
stimulation by MDP or Mur-Tri-DAP (Fig. 4A). In contrast,
after stimulation for 4 h with an anti-TREM-1 agonistic anti-
body, the level of steady-state NOD2 mRNA was significantly
higher compared with that of IgG1-stimulated cells, in each
four PBMC preparations tested (Fig. 4B). GAPDH levels were
similar in each sample (not shown). Consistent with the in-
crease of NOD2 expression, PBMC treated with the anti-
TREM-1 antibody exhibited an increased response to low
concentrations of MDP (Fig. 4C).
The role of caspase-1 in the synergistic effects
of TREM-1 on NLR stimulation
Proinflammatory caspases, such as caspase-1 and caspase-5,
interact with the caspase-associated recruitment domain
(CARD) of NLRs, resulting in the processing of the proinflam-
matory cytokines IL-1 and IL-18 [21]. As IL-1 often con-
trols IL-6 production, proinflammatory caspases also influence
the production of the latter cytokine. To investigate whether
caspase activation contributes to the synergistic effects of
TREM-1 and muropeptides, the effect of a pan-caspase inhib-
itor, a specific caspase-1 inhibitor, and of a caspase1/5 inhib-
itor on the synergistic effects between TREM-1 and MDP (Fig.
5 A–C) or Mur-Tri-DAP (Fig. 5, D–F) was examined. Whereas
the synergy between TREM-1 and the muropeptides for the
stimulation of TNF was not significantly influenced by the
caspase inhibitors (Fig. 5, A and D), the amplification of
Fig. 3. TREM-1 synergizes with TLR and NLR ligands. Human PBMC were incubated in wells coated with anti-TREM-1 antibodies in the presence of ligands
of TLRs: LPS (10 ng/ml), LTA (5 g/ml), poly I:C (5 g/ml), flagellin (100 ng/ml), CpG DNA (10 g/ml), and the muropeptide ligands of NLRs: MDP (10 g/ml)
and Mur-Tri-DAP (10 g/ml). TNF- (A, C) and IL-6 (B, D) concentrations were measured by ECL after 24 stimulation. Hatched bars represent the stimulation
induced by the combination of the anti-TREM-1 antibodies with the TLR/NLR ligands, and open bars are stimulations with TLR/NLR ligands alone. Data are
presented as means  SEM (n6); *, P 	 0.05.
Netea et al. TREM-1 amplifies NLR signals 1457
NLR-induced IL-1 (Fig. 5, B and E) and IL-6 (Fig. 5, C and
F) was reduced by a pan-caspase inhibitor and a caspase-1
inhibitor (80–90% reduction). An inihibitor blocking
caspase-5 and caspase-1 had no additional effects on the
synergism on top of the specific caspase-1 inhibitor.
The effects of caspase-1 inhibition on IL-6
production is a result of endogenous IL-1
As caspase-1 does not directly influence IL-6 production, we
sought to investigate whether this effect could be mediated by
endogenous IL-1 or IL-18. The amplification of the IL-6
production induced by NLR ligands MDP and Mur-Tri-DAP by
engagement of TREM-1 was investigated under IL-1R block-
ade with saturating concentrations of IL-1Ra or neutralizing
concentrations of IL-18BP. As shown in Figure 6, IL-1Ra
inhibited the synergism between TREM-1 and the muropep-
tides, demonstrating that the effects of caspase-1 on IL-6
release depend on neutralization of endogenous IL-1 activity.
In contrast, IL-18BP had no effect on the synergism between
TREM-1 and muropeptides (Fig. 6).
DISCUSSION
The novel finding of the present study is that engagement of
TREM-1 amplifies not only TLR signals but also the NLR
stimulation induced by the muropeptide components of pepti-
doglycan. This observation has a considerable biological rele-
vance, as peptidoglycans are structures common to all clini-
cally important bacteria, including mycobacteria. The ampli-
fication was observed for the production of TNF-, IL-1, and
IL-6, leading to an increase in cytokine production up to
tenfold greater than the additive value of TREM-1 or muropep-
tide stimulation alone. Several putative mechanisms appear to
account for these effects: on the one hand, NLR ligands mod-
erately stimulate TREM-1 expression, whereas an increase in
NOD2 gene expression has been induced by TREM-1 stimu-
lation. In addition, TREM-1/NOD2 amplification of IL-1 and
IL-6 was strongly inhibited by a caspase-1 inhibitor. Thus,
these findings support the concept that TREM-1 is an ampli-
fication route for both major responses to bacterial recognition:
the extracellular TLRs and the intracellular NLR molecules.
TREM-1 engagement by agonist antibodies induces produc-
tion of the proinflammatory cytokines TNF-, IL-1, and IL-6
as well as production of chemokines, as described previously
[9–11]. This stimulation was dependent on the presence of
serum, and we demonstrate here that the serum effect is
independent of the intermediary production of endogenous
TNF-, IL-1, or IL-18, as their specific inhibitors did not
influence the effects of TREM-1 stimulation. It is presently
unclear why stimulation of cytokines by anti-TREM-1 antibod-
ies is dependent on serum, although others [10] have also
observed this. Cross-linking between a serum component and
anti-TREM-1 antibodies on the one hand and membrane
TREM-1 on the other may represent a possible explanation.
Thus, a direct, proinflammatory action accounts for the cyto-
kines induced by TREM-1 engagement. Experimental models
of endotoxic shock support an important role of TREM-1 in
systemic inflammation, in which blockade of TREM-1 results
in improved survival [12, 22]. In addition, studies in a model
of endotoxemia in human volunteers revealed that the expres-
sion of TREM-1 was up-regulated after challenge with LPS
[23]. Increased levels of soluble TREM-1 (sTREM-1) have
been measured in patients with septic shock [24, 25], and
sTREM-1 has been proposed as an additional parameter of
inflammation during severe infections [26].
The NLR family members NOD1, NOD2, and NALP3 are
PRRs for the muropeptide components of bacterial peptidogly-
cans. They recognize different motifs of bacterial peptidogly-
can: NOD1 recognizes the Mur-Tri-DAP of Gram-negative
bacteria, which contains a meso-diaminopimelic acid in the
third position of the peptidoglycan stem peptide [17], whereas
NOD2 and NALP3 interact with MDP of Gram-positive bacte-
ria, containing a lysine residue in the same position [14, 15].
By recognizing these specific motifs, NLRs are able to discrim-
inate between Gram-negative and Gram-positive bacteria. This
important feature of NLR, together with the ubiquitous pres-
ence of peptidoglycans in the structure of Gram-positive and
Gram-negative bacteria and with the interaction of TLR and
NOD pathways [27–30], results in a vital role for NLRs in the
process of bacterial recognition and host defense. Studies in
Fig. 4. TREM-1 activation induces the expression of NOD2. (A) Human
PBMC were stimulated with a panel of TLR and NLR stimuli. After 24 h, the
levels of TREM-1 protein in the cell lysates were measured by a specific
ELISA (n6, meansSEM). (B) After stimulation for 4 h with an anti-TREM-1
agonistic antibody, steady-state levels of NOD2 mRNA were determined by
RT-PCR. Incubation of PBMC from four separate individuals is shown in the
presence of a control IgG1 antibody (Lanes 1, 3, 5, and 7) or the anti-TREM-1
antibody (Lanes 2, 4, 6, and 8). (C) To investigate the effect of TREM-1
engagement on low concentrations of MDP stimulation, PBMC were added to
wells coated with the anti-TREM-1 antibody and then stimulated with MDP in
concentrations ranging from 0.1 to 10 g/ml. Data are presented as means 
SEM (n6); *, P 	 0.05.
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mice deficient in NOD2 reveal defective defensin production
and increased susceptibility to intracellular pathogens [31, 32],
whereas patients with Crohn’s disease and homozygous for the
3020insC mutation in the LRR domain of NOD2 display de-
fective MDP recognition, with absence of NF-B activation and
cytokine release [15, 27, 28, 30]. The present study is the first
to demonstrate that TREM-1 synergizes with the muropeptide
NLR ligands and implies that TREM-1 has a central role in
inflammation, as it is an amplification signal for the two major
classes of PRRs: TLRs and NLRs.
The synergism between TREM-1 and TLR/NLRs can have
positive effects, as it would assure an efficient activation of host
defense. However, a negative consequence is also possible as
a result of induction of overwhelming inflammation. The pro-
tection of mice by the TREM-1 blockade in a model of lethal
endotoxemia [12, 22] as well as experiments in mice overex-
pressing DAP12, who are highly susceptible to LPS-induced
shock [33], are arguments in this latter respect. When consid-
ering the synergism between TREM-1 and NLR activation, it is
important to remember the recent report of Schenk and col-
leagues [34], who demonstrated the low expression of TREM-1
in macrophages from intestine and colon compared with my-
eloid cells from the circulation, lymph nodes, or tonsils. As
muropeptide recognition in the colon by the NLR family mem-
Fig. 5. The role of caspase-1 in the amplification of NLR-induced cytokines by TREM-1 engagement. PBMC were added to wells coated with an anti-TREM-1
antibody (aTREM-1; or mouse IgG1) and then stimulated with the NLR ligands MDP or Mur-Tri-DAP. The effects of a pan-caspase inhibitor (casp-inh), a caspase-1
inhibitor (casp-1i), and of a caspase1/5 inhibitor (casp1/5i; each at 20 mM) on the synergistic effects between TREM-1 and MDP (A–C) or Mur-Tri-DAP (D–F)
were investigated. The stimulation of cells in the absence of caspase inhibitors is defined in the figure as “control” stimulation. TNF- (A, D), IL-1 (B, E), and
IL-6 (C, F) concentrations were measured after 24 h stimulation. Data are presented as means  SEM (n6); *, P 	 0.05, compared with the stimulation without
caspase inhibitors.
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ber NOD2 appears to be a crucial event in the pathogenesis of
Crohn’s disease [35, 36], it is tempting to speculate that the low
expression of TREM-1 in the intestine represents a protective
mechanism against an overwhelming inflammation, which
could be induced by the interaction of NOD2 and TREM-1
pathways.
It seems unlikely that an increase in TREM-1 expression by
muropeptides (or TLR ligands) could play the main role in
these effects: only 50% increase of the TREM-1 expression has
been observed after stimulation of PBMC with TLR or NLR
stimuli. However, engagement of TREM-1 increased the ex-
pression of NOD2 mRNA in each of the four volunteers. The
enhancement of NOD2 expression by TREM-1 ligation was
accompanied by increased sensitivity to low concentrations of
MDP, and this may suggest a role of increased NOD2 expres-
sion in this synergism. In addition, the TREM-1/NLR syner-
gism on IL-1 and IL-6 production was partially down-regu-
lated by inhibitors of caspase-1. The CARD domain of NLR
proteins interacts with caspase-1 and caspase-5, and this re-
sults in the processing of cytokine precursors such as pro-
IL-1 and pro-IL-18 [21, 37]. A pan-caspase inhibitor and a
specific caspase-1 inhibitor significantly (65–80%) reduced
MDP-induced cytokines and the synergism between TREM-1
and muropeptides. Additional inhibition of caspase-5 by a dual
inhibitor of caspase-1 and -5 did not have an additional effect
on the TREM-1/NLR stimulation. These observations are con-
sistent with a report showing that NOD1 interacts with
caspase-1, enhancing the processing of pro-IL-1 [37]. Al-
though this could suggest a possible role of caspase-1 in the
TREM-1/NLR synergism, the effects of caspase-1 inhibition on
NLR stimulation alone also may signify an effect of caspase-1
on NLR activation of the inflammasome and not on the syner-
gism with TREM-1. In addition, using specific inhibitors of
IL-1 and IL-18 activity, we demonstrate that although
caspase-1 activation is responsible for the synergistic effects of
TREM-1 and MDP on IL-1 production, it is IL-1 and not
IL-18 that accounts for the secondary effect on IL-6 synthesis.
Conversely, NOD2 activates the serine/threonine kinase recep-
tor-interacting protein 2/RICK/CARDIAK, and this leads to
NF-B activation and transcription of proinflammatory cyto-
kine genes such as TNF-, IL-1, and IL-6 [38]. The activa-
tion of this pathway may be potentiated by the increased NOD2
expression following TREM-1 engagement.
It is known that the short intracellular domain of TREM-1
associates with the adaptor molecule DAP12. Therefore, it is
reasonable to hypothesize that the amplification signals in-
duced by TREM-1 follow a DAP12-dependent route. This
hypothesis is strengthened by a study showing increased in-
flammation in mice engineered to overexpress DAP12 [33].
This is in contrast to a report suggesting enhanced TLR re-
sponses in mice deficient in DAP12, which suggests that
DAP12 is a negative regulator of TLR signaling [39], but is
consistent with a study showing that DAP12 amplifies inflam-
mation in models of endotoxemia and septic peritonitis [40].
Whether TREM-1 amplifies TLR and NLR signaling through a
DAP12-independent mechanism or whether other DAP12-in-
dependent signals are responsible for the effects of TREM-1
remains to be elucidated. In addition, the nature of the natural
agonist(s) of TREM-1 is yet to be found. Bacterial components
have been reported to be ligands of TREM-2 [41], but no such
reports have been published for TREM-1. Nevertheless, the
Ig-like structure of TREM-1 is reminiscent of cytokine recep-
tors rather than PRRs. However, the true nature of the TREM-1
ligand(s) remains to be elucidated.
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